ITRM ITERUM THERAPEUTICS PLC Capital Structure Changes 8-K Filing 2024 - Milestone Payment Deferral Iterum Therapeutics agreed to defer a $20 million milestone payment to Pfizer for FDA approval of its drug ORLYNVAH until October 2026, with an 8% interest rate on the deferred amount.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC